Valuation: Soligenix, Inc.

Market Cap 7.48M 6.66M 6.18M 5.59M 10.52M 709M 10.67M 73.91M 29.05M 371M 28.06M 27.48M 1.18B P/E 2026 *
-0.62x
P/E 2027 * -0.86x
Enterprise Value 7.48M 6.66M 6.18M 5.59M 10.52M 709M 10.67M 73.91M 29.05M 371M 28.06M 27.48M 1.18B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
95.41%
Yield 2026 *
-
Yield 2027 * -
1 day+3.17%
1 week+0.82%
Current month-2.04%
1 month-4.16%
3 months-1.23%
6 months-71.63%
Current year-73.54%
1 week 0.32
Extreme 0.3248
0.36
1 month 0.32
Extreme 0.3248
0.39
Current year 0.28
Extreme 0.28
1.49
1 year 0.28
Extreme 0.28
1.71
3 years 0.28
Extreme 0.28
32
5 years 0.28
Extreme 0.28
256.68
10 years 0.28
Extreme 0.28
1,260
Manager TitleAgeSince
Chief Executive Officer 59 31/07/2006
Director of Finance/CFO 53 10/09/2019
Chief Tech/Sci/R&D Officer - 10/06/2026
Director TitleAgeSince
Chairman 59 07/10/2009
Director/Board Member 67 28/02/2009
Director/Board Member 80 30/09/2009
Date Insider Type Main position Quantity % Market Cap. Importance
12/10/26 Issuer sale

Chief Financial Officer

-914 0.0042%
12/10/26 Issuer sale

Chief Technology Officer

-1,559 0.0072%
12/10/26 Issuer sale

Director

-632 0.0029%
Change 5-day change 1-year change 3-year change Capi.($)
+3.17%+0.82%-78.51%-95.77% 7.48M
+0.79%-6.46%+52.86%+71.34% 65.83B
+1.92%+8.89%+12.90%+82.75% 51.87B
+6.91%+6.41%+9.61%+73.07% 51.2B
+0.74%+2.15%+30.95%+43.43% 43.76B
+3.87%+9.73%+21.52%+142.33% 42.09B
+7.91%+1.34%+263.31%+577.76% 39.04B
-0.40%+9.42%+18.44%+59.06% 34B
+3.84%-4.94%+42.35%+8.92% 25.2B
+2.36%+4.62%+24.20%+31.02% 22.8B
Average +3.11%+0.23%+39.76%+99.39% 37.58B
Weighted average by Cap. +3.05%+0.62%+51.69%+122.71%

Financials

2026 *2027 *
Net sales - -
Net income -9.3M -8.28M -7.68M -6.95M -13.08M -881M -13.27M -91.88M -36.11M -461M -34.88M -34.16M -1.47B -10.1M -8.99M -8.34M -7.55M -14.2M -957M -14.41M -99.79M -39.22M -501M -37.88M -37.1M -1.6B
Net Debt - -
Projected Income Statement - Annual - Soligenix, Inc.
Logo Soligenix, Inc.
Soligenix, Inc. is a late-stage biopharmaceutical company, which is focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company’s segments include Specialized Biotherapeutics, and Public Health Solutions. Its Specialized BioTherapeutics business segment is engaged in developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious diseases and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2).
Employees
14
Date Price Change Volume
20/10/26 US$0.3546 +3.17% 81,011
19/10/26 US$0.3437 -2.66% 69,758
16/10/26 US$0.3531 -0.56% 218,746
15/10/26 US$0.3551 +4.23% 172,480
14/10/26 US$0.3407 +1.76% 148,231
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Soligenix, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.3546USD
Average target price
1.375USD
Spread / Average Target
+287.76%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Soligenix, Inc.
  1. Stock Market
  2. Stocks
  3. SNGX Stock